Related Experiment Videos
[Prognosis of interstitial pneumonitis (IP) in polymyositis (PM)/dermatomyositis (DM)]
T Saeki1, E Suzuki, T Watanabe
1Department of Medicine (II), Niigata University School of Medicine.
Abstract:
IP, the major complication of PM/DM, is closely related to the life of these patients. In this study the course and prognosis of IP associated with PM/DM were investigated. Thirty IP patients with PM/DM were divided into 4 groups according to the course of IP. Clinical manifestations, laboratory data, chest radiographs and treatment were examined retrospectively. Eleven cases improved (Group I), 11 cases were exacerbated (Group E), 3 cases were unchanged (Group U), 2 cases died due to rapid progression of IP (Group D) and 3 cases dropped out. Both Group D patients were middle aged female DM patients without CPK elevation. All cases were treated with corticosteroids. The clinical manifestations, laboratory data, chest radiographs and initial dose of corticosteroid were not markedly different between Group I and E. The total dose of corticosteroids during the first 3 months tended to be higher in Group I than in Group E. Unlike idiopathic interstitial pneumonitis, the decrease in lung volume on chest radiographs improved after the treatment in 5 cases. We conclude that IP associated with PM/DM should be treated initially with high doses of corticosteroids.
Insights
Interstitial pneumonia (IP) in polymyositis/dermatomyositis (PM/DM) requires prompt high-dose corticosteroid treatment for better outcomes. Early high-dose steroids may improve lung function and prognosis in these patients.
Area of Science:
- Pulmonology
- Rheumatology
- Immunology
Context:
- Interstitial pneumonia (IP) is a severe complication of polymyositis/dermatomyositis (PM/DM).
- The course and prognosis of IP in PM/DM patients significantly impact patient survival.
- Understanding IP progression in PM/DM is crucial for effective management.
Purpose:
- To investigate the clinical course and prognosis of interstitial pneumonia (IP) in patients with polymyositis/dermatomyositis (PM/DM).
- To analyze clinical manifestations, laboratory data, radiographic findings, and treatment responses in different IP progression groups.
Summary:
- Thirty IP patients with PM/DM were retrospectively analyzed and categorized into improvement, exacerbation, unchanged, and death groups.
- Corticosteroid treatment was administered to all patients; higher total doses in the first 3 months correlated with improvement.
- Unlike idiopathic IP, chest radiograph lung volume reductions improved with treatment in some PM/DM cases.
Impact:
- High-dose corticosteroid therapy is recommended for initial treatment of IP associated with PM/DM.
- This approach may improve lung function and patient outcomes in this specific patient population.
- Findings guide clinical decision-making for managing this severe complication of PM/DM.